Literature DB >> 22816982

Low-dose acyclovir prophylaxis for bortezomib-induced herpes zoster in multiple myeloma patients.

Jiri Minarik, Tomas Pika, Jaroslav Bacovsky, Katerina Langova, Vlastimil Scudla.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22816982     DOI： 10.1111/j.1365-2141.2012.09233.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN： 0007-1048            Impact factor:   6.998


× No keyword cloud information.
  6 in total

Review 1.  Current treatment landscape for relapsed and/or refractory multiple myeloma.

Authors:  Meletios A Dimopoulos; Paul G Richardson; Philippe Moreau; Kenneth C Anderson
Journal:  Nat Rev Clin Oncol       Date:  2014-11-25       Impact factor: 66.675

2.  Importance of Compliance With Guidelines for the Prevention of Varicella-Zoster Virus Reactivation in Multiple Myeloma.

Authors:  Yasukata Ohashi; Megumi Yatabe; Daisuke Niijima; Arina Imamura; Yoshiyuki Nagayama; Kentaro Otsuka; Yutaka Yachi; Hironori Ueno; Takahiro Yano; Nobuaki Mori; Koji Higai; Akihiro Yokoyama
Journal:  In Vivo       Date:  2021 Nov-Dec       Impact factor: 2.155

Review 3.  Clinical use of proteasome inhibitors in the treatment of multiple myeloma.

Authors:  Noah M Merin; Kevin R Kelly
Journal:  Pharmaceuticals (Basel)       Date:  2014-12-24

4.  Survival benefit of ixazomib, lenalidomide and dexamethasone (IRD) over lenalidomide and dexamethasone (Rd) in relapsed and refractory multiple myeloma patients in routine clinical practice.

Authors:  Jiri Minarik; Tomas Pika; Jakub Radocha; Alexandra Jungova; Jan Straub; Tomas Jelinek; Ludek Pour; Petr Pavlicek; Martin Mistrik; Lucie Brozova; Petra Krhovska; Katerina Machalkova; Pavel Jindra; Ivan Spicka; Hana Plonkova; Martin Stork; Jaroslav Bacovsky; Lenka Capkova; Michal Sykora; Petr Kessler; Lukas Stejskal; Adriana Heindorfer; Jana Ullrychova; Tomas Skacel; Vladimir Maisnar; Roman Hajek
Journal:  BMC Cancer       Date:  2021-01-15       Impact factor: 4.430

5.  Management of herpesvirus reactivations in patients with solid tumours and hematologic malignancies: update of the Guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society for Hematology and Medical Oncology (DGHO) on herpes simplex virus type 1, herpes simplex virus type 2, and varicella zoster virus.

Authors:  Larissa Henze; Christoph Buhl; Michael Sandherr; Oliver A Cornely; Werner J Heinz; Yascha Khodamoradi; Til Ramon Kiderlen; Philipp Koehler; Alrun Seidler; Rosanne Sprute; Martin Schmidt-Hieber; Marie von Lilienfeld-Toal
Journal:  Ann Hematol       Date:  2022-01-07       Impact factor: 3.673

6.  Efficacy of Intermittent, Oral Famciclovir Prophylaxis for Bortezomib-Induced Herpes Zoster in Multiple Myeloma Patients.

Authors:  Gaofeng Zheng; Fangshu Guan; Xiaoyan Han; Li Yang; Yi Zhao; Yang Yang; Enfang Zhang; Jingsong He; Donghua He; Wenjun Wu; He Huang; Zhen Cai
Journal:  Front Oncol       Date:  2022-03-11       Impact factor: 6.244
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.